Skip to main content
Download PDF

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies

Breast Cancer Research volume 25, Article number: 1 (2023) Cite this article

Abstract

Background

Breast cancer mortality is principally due to recurrent disease that becomes resistant to therapy. We recently identified copy number (CN) gain of the putative membrane progesterone receptor PAQR8 as one of four focal CN alterations that preferentially occurred in recurrent metastatic tumors compared to primary tumors in breast cancer patients. Whether PAQR8 plays a functional role in cancer is unknown. Notably, PAQR8 CN gain in recurrent tumors was mutually exclusive with activating ESR1 mutations in patients treated with anti-estrogen therapies and occurred in > 50% of both patients treated with anti-estrogen therapies and those treated with chemotherapy or anti-Her2 agents.

Methods

We used orthotopic mouse models to determine whether PAQR8 overexpression or deletion alters breast cancer dormancy or recurrence following therapy. In vitro studies, including assays for colony formation, cell viability, and relative cell fitness, were employed to identify effects of PAQR8 in the context of therapy. Cell survival and proliferation were quantified by immunofluorescence staining for markers of apoptosis and proliferation. Sphingolipids were quantified by liquid chromatography-high resolution mass spectrometry.

Results

We show that PAQR8 is necessary and sufficient for efficient mammary tumor recurrence in mice, spontaneously upregulated and CN gained in recurrent tumors that arise following therapy in multiple mouse models, and associated with poor survival following recurrence as well as poor overall survival in breast cancer patients. PAQR8 promoted resistance to therapy by enhancing tumor cell survival following estrogen receptor pathway inhibition by fulvestrant or estrogen deprivation, Her2 pathway blockade by lapatinib or Her2 downregulation, and treatment with chemotherapeutic agents. Pro-survival effects of PAQR8 were mediated by a Gi protein-dependent reduction in cAMP levels, did not require progesterone, and involved a PAQR8-dependent decrease in ceramide levels and increase in sphingosine-1-phosphate levels, suggesting that PAQR8 may possess ceramidase activity.

Conclusions

Our data provide in vivo evidence that PAQR8 plays a functional role in cancer, implicate PAQR8, cAMP, and ceramide metabolism in breast cancer recurrence, and identify a novel mechanism that may commonly contribute to the acquisition of treatment resistance in breast cancer patients.

Background

Breast cancer is the most frequently diagnosed cancer and leading cause of cancer-related death among women worldwide [1]. Most deaths from breast cancer are due to treatment-refractory recurrences that occur months or years after definitive treatment of the primary tumor [2]. Consequently, a better understanding of the mechanisms underlying disease recurrence, particularly therapy resistance, is essential for improving patient outcomes.

Systemic therapies for breast cancer, including anti-estrogen therapies, anti-Her2 therapies, and chemotherapy, are selected based upon tumor subtype (i.e., estrogen receptor and Her2 status), tumor stage, lymph node status, and other biological features relevant to risk stratification. Despite advances in treatment, however, up to 30% of patients eventually develop recurrent disease, which is typically incurable due to therapy resistance that develops to each of these classes of agents [2]. Thus, resistance to therapy is a core feature of breast cancer progression that is disproportionately responsible for mortality.

To address this critical gap in knowledge, Paul et al. [3] recently performed whole exome and shallow whole genome sequencing of paired primary and recurrent breast cancers in patients in the METAMORPH study who had undergone anti-estrogen therapy, chemotherapy, and/or anti-HER2 therapy prior to tumor recurrence. Across the genome, only four regions with copy number (CN) alterations were determined to be preferentially enriched in recurrent, compared to primary, tumors, including preferential CN loss of the tumor suppressors STK11/LKB1 and CDKN2A, and preferential CN gain of PTK6. A fourth focal 78 kbp region on chromosome 6p12.2 exhibited preferential CN gain in recurrent tumors and contained the entire coding sequence of only a single gene, PAQR8. To date, an in vivo role for PAQR8 in cancer has not been reported, and little is known about its function or mechanism of action.

Given that STK11/LKB1, CDKN2A, and PTK6 each have well-described roles in cancer progression [4,5,6], we hypothesized that PAQR8 might play a role in breast cancer recurrence. A clue to its potential role came from the finding that, in patients treated with anti-estrogen therapy, PAQR8 CN gain in recurrent tumors was mutually exclusive with activating point mutations in ESR1, as well as mutations in PGR [3]. ESR1 mutations occur in up to 20% of recurrent breast cancers arising in patients treated with anti-estrogen therapies and occur almost exclusively in patients treated with aromatase inhibitors [7, 8]. Since activating ESR1 mutations confer resistance to anti-estrogen therapy, this mutually exclusive pattern suggested that PAQR8 might play a redundant role in this process, whether by activating a downstream mediator of the estrogen receptor (ER) itself or an alternative resistance pathway.

Notably, PAQR8 CN gain in recurrent breast cancers was not restricted to patients who received anti-estrogen therapy as it was found with equal frequency among patients treated with other therapies, including chemotherapy and agents targeting Her2. These findings suggested the intriguing possibility that PAQR8 might promote a more generalized form of therapy resistance and, in that way, contribute to tumor recurrence.

PAQR8, also known as mPRβ, is a member of the membrane progesterone receptor (mPR) subclass of the progestin and adipoQ receptor (PAQR) family [9, 10]. PAQR8 expression has been detected in a variety of cell types, including normal and malignant breast, ovarian, and myometrial cells [11,12,13]. Its function is poorly understood, and there have been conflicting reports regarding PAQR8 structure, function, and ability to bind and respond to progesterone [11, 14,15,16].

Membrane progesterone receptors have been reported to mediate rapid effects of progesterone signaling. Although residues that disrupt progesterone binding when mutated have recently been reported for the related mPR family member, PAQR7 [17], a progesterone binding site for PAQR8 has not been identified. While siRNA knockdown of PAQR8 in cells has been reported to reduce membrane progesterone binding, it did not affect progesterone-mediated downstream functions [11, 18]. Further, in a yeast model in which human PAQR8 was expressed, progesterone was not required for activity [19]. Thus, whether progesterone plays a role in PAQR8 function remains uncertain.

Based on computational predictions, PAQR8 has been proposed to be a 7-transmembrane protein with an extracellular N-terminus and intracellular C-terminus resembling GPCRs [9, 10]. Consistent with a GPCR-like function, some evidence suggests that effects of PAQR8 and other mPRs may be mediated by coupling to an inhibitory G (Gi) protein [11, 20]. However, there is as yet no direct evidence that PAQR8 acts to decrease intracellular cAMP levels in a manner that is sensitive to pertussis toxin (PTX), a potent inhibitor of GPCRs coupled to Gi proteins [21].

It has also been proposed that PAQR8 might potentially function as an alkaline ceramidase based on the presence of three motifs conserved across the entire PAQR family that resemble motifs conserved within the alkaline ceramidase family with respect to both sequence and location [22, 23]. Indeed, the yeast PAQR protein Izh2p, as well as human adiponectin receptors PAQR1 and PAQR2, have been reported to possess intrinsic ceramidase activity [24, 25]. However, no evidence to date has shown that PAQR8 can alter levels of ceramides or other sphingolipids in eukaryotic cells.

In this study, we examined the role of PAQR8 in breast cancer recurrence and resistance to therapy. Our data indicate that PAQR8 plays a functional role in cancer progression by demonstrating that PAQR8 is both necessary and sufficient to promote efficient breast cancer recurrence and that PAQR8 confers resistance to each of the classes of therapeutic agents commonly used in breast cancer patients by enhancing cell survival, and does so independently of progesterone. We further show that the pro-survival effects of PAQR8 in cancer cells are dependent upon a Gi protein-mediated reduction in intracellular cAMP levels and demonstrate that PAQR8 alters the balance of ceramides and sphingolipids in a manner predicted to promote cell survival. Consistent with a clinically relevant role in breast cancer, we found that PAQR8 is spontaneously upregulated and CN gained in post-therapy recurrent tumors from multiple mouse models and is associated with breast cancer progression and poor survival in patients. Together, our data support a model in which PAQR8 promotes breast cancer recurrence by facilitating resistance to multiple antineoplastic therapies in a manner that alters ceramide levels and requires coupling to a Gi protein.

Methods

Genomic data

Within the METAMORPH cohort [3, 26], the association between mutations in ESR1, mutations in PGR, or gain of PAQR8 with survival following clinical progression after recurrence was assessed using Cox proportional hazards regression. Variant and copy number calling methodologies were previously described [3].

Within the TCGA BRCA cohort [8], survival data and copy number calls from GISTIC2 were obtained from the NIH Genomic Data Commons (GDC) portal [27]. + 1 and + 2 GISTIC2 calls were considered to represent low- and high-level gain, respectively. Associations with PAQR8 gain were assessed using Cox proportional hazards regression.

For primary and recurrent tumors arising in GEM models, CN change calls were identified using shallow whole genome sequencing (75 bp single-end reads, 30.1 million reads on average, 0.9X coverage), alignment using BWA [28], CN signal quantification using QDNAseq [29], and CN normalization using ACE [30]. Low-level CN gains (≥ 2.12) were defined as CN calls that were detected above the threshold that contained > 99% of copy number calls in normal tissue samples. The threshold for high-level CN gain (≥ 2.9) was defined based on the ability to encompass the majority of the CN distribution peak at CN = 3. Low-level gains were considered to represent subclonal CN events, and high-level gains were considered to represent either clonal + 1 CN events or subclonal >  + 1 CN events. Frequencies of CN gain were compared between primary and recurrent tumors using one-sided Fisher’s exact test. mRNA expression was assayed following TruSeq RNA library preparation and sequencing (100 bp paired-end reads, 30 M reads on average), followed by STAR alignment [31], read quantification by featureCounts [32], and read normalization using DESeq2 [33]. Normalized read counts for Paqr8 were compared using Wilcoxon rank-sum test.

Tissue culture

Inducible Her2-dependent primary mouse tumor cells were cultured as described [34]. MCF7, BT474-M1 cells, and SUM159 cells were purchased from ATCC and cultured as recommended. Charcoal-stripped serum was purchased from Sigma-Aldrich (#F6765, lot 18L289).

Viable cell numbers were measured using a Vi-CELL cell counter (BD Biosciences). For colony formation assays, cells were plated in 6-well plates in complete growth medium and then shifted to the specified test medium 24 h later. Colonies were fixed and stained with crystal violet for visualization and quantified manually.

Drugs

Lapatinib (#S2111), doxorubicin (#S1208), and docetaxel (#S1148) were purchased from Selleck Chemicals. Fulvestrant (#I4409) and pertussis toxin (#P7208) were purchased from Sigma-Aldrich. Forskolin was purchased from Abcam (#ab120058).

Plasmids and lentivirus production

Plasmids pUltra (#24129) and pUltra-hot (#24130) were purchased from Addgene. The eGFP and mCherry alleles were replaced with H2B-eGFP and H2B-mCherry from Addgene plasmids #11680 and #20972, respectively. Human and mouse PAQR8 cDNA sequences were synthesized by Integrated DNA Technologies, sequence-verified, and cloned into the above-modified pUltra plasmid. Sense and anti-sense oligos for each sgRNA were ligated into BsmB1-digested LRG2.1 vector (Addgene #108098) or LRmCherry2.1 vector (Addgene #108099). Lentivirus was produced by transfecting HEK293T cells with polyethylenimine (Polysciences #23966), pMD2.G (Addgene #12259), psPAX2 (Addgene #12260), and the plasmid of interest.

Mouse experiments

Animal care and experiments were performed in accordance with the guidelines of the University of Pennsylvania IACUC. Recurrence assays were performed as described [34, 35]. Briefly, 1 × 106 cells were injected into the inguinal mammary fat pads of female nu/nu mice. Mice were maintained on 2 mg/ml doxycycline in drinking water until primary tumors reached 5 × 5 mm. Mice were palpated 2–3 times weekly for tumor recurrence. To form MCF7 tumors, 2.5 × 106 MCF7 cells were injected into the inguinal mammary fat pads of female NSG mice. Mice were palpated twice weekly for tumor formation and sacrificed when tumors reached 8 × 8 mm. All mice were injected with 50 mg/kg EdU (i.p.) 2 h prior to sacrifice.

Droplet digital PCR

Genomic DNA isolation from cells was performed using the QIAamp DNA mini kit (Qiagen #51306) following manufacturer’s instructions. Genomic DNA isolation from tissue was performed using Zymo Quick-DNA Midiprep Plus kit (Zymo Research #D4075) following manufacturer’s instructions. Probes were all purchased from Bio-Rad, including eGFP (#dCNS372378948), mCherry (#dCNS507694046), and ApoB (#dMmuCNS407594696). Droplets were generated and read using the QX200 AutoDG Droplet Digital PCR System (Bio-Rad). PCR was performed using the C1000 Touch Thermal Cycler (Bio-Rad).

Immunofluorescence

Mammary tumors were fixed in 4% PFA, dehydrated, and embedded in paraffin blocks. Paraffin tissue sections 8 µm thick were prepared using a standard xylene-based dewaxing procedure [36]. Sections were subjected to antigen retrieval in Buffer A or B (Electron Microscopy Sciences) using a 2100 Retriever (Diagnostic Technology). Cells grown on coverslips were fixed in 4% PFA and permeabilized in 0.5% Triton X-100. Blocking was performed in 3% BSA and 5% normal goat serum for 1 h before overnight incubation at 4 °C with primary antibodies. Samples were incubated with secondary antibodies for 1 h at room temperature followed by Hoechst staining for nuclei. Slides were visualized on a DM 5000B Automated Upright Microscope (Leica), and images were captured with a DFC350 FX monochrome digital camera (Leica). Images were quantified using QuPath-0.3.0 software [37].

Antibodies

Primary antibodies and dilutions included: chicken anti-GFP (Abcam #ab13970; 1:1000), mouse anti-GFP (Living Colors #JL-8; 1:250), rabbit anti-cleaved caspase-3 (Cell Signaling #9664; 1:250), rat anti-Ki67 (eBioscience #14-5698; 1:100), rat anti-HA (Roche #3F10; 1:1000), and anti-β-tubulin (BioGenex #MU122-UC; 1:5000). EdU detection: In Vivo EdU Click Kit 647 (Sigma-Aldrich #BCK647-IV-IM-S), in vitro Click-iT Plus EdU Cell Proliferation Kit for Imaging Alexa Fluor 647 dye (Thermo Fisher Scientific #C10640). Secondary Alexa-conjugated antibodies (Invitrogen; 1:1000) included: goat anti-chicken IgG Alexa-488 (#A11039), goat anti-mouse IgG2A Alexa-488 (#A21131), goat anti-rabbit IgG Alexa-594 (#A11012), and goat anti-rat IgG Alexa-568 (#A11077). Secondary IRDye-conjugated antibodies (LiCor; 1:10,000) included: 680LT anti-mouse IgG1 (#926-68050) and 800CW anti-rat IgG (#926-32219).

cAMP

Intracellular cAMP levels were measured using a fluorometric competitive ELISA assay kit (Abcam #ab138880) following manufacturer’s instructions.

Liquid chromatography-high resolution mass spectrometry

Sphingolipid extraction was performed as described [38] after adding 1 mL of 80% methanol to each plate to inactivate enzymes. Each experimental condition had five technical replicates, with the sixth used for protein quantification. Sphingolipids levels were normalized to protein content.

Statistics

Two-tailed Student’s t tests were used to assess differences between groups, with the exception of the Mann–Whitney U test that was employed for data that were not normally distributed, as determined by the Shapiro–Wilk test. Survival curves were generated using the Kaplan–Meier method, with P values and hazard ratios calculated by the Mantel–Haenszel method and log-rank test for trend. P < 0.05 was considered statistically significant. In vitro analyses are representative of at least three independent experiments.

Results

PAQR8 gain is associated with breast cancer progression

Based on our findings in breast cancer patients in the METAMORPH study that PAQR8 undergoes preferential CN gain in recurrent tumors, and that PAQR8 CN gain is mutually exclusive with activating mutations in ESR1 (Fig. 1A) [3], we sought to determine whether PAQR8 gain was associated with clinical progression in this patient cohort [3]. Indeed, we found that patients treated with anti-endocrine therapies whose recurrent tumors harbored PAQR8 gain, ESR1 mutations, or PGR mutations had significantly poorer survival following clinical progression (p = 0.003, HR = 3.4) (Fig. 1B). Notably, survival outcomes for patients whose recurrent tumors harbored PAQR8 gain were comparable to those with ESR1 activating mutations (p = 0.6) (Fig. 1B).

Fig. 1
figure 1

PAQR8 gain in human and mouse tumors is associated with recurrence and disease progression. A Patients in the METAMORPH cohort, depicting receptor status in primary (Pri) and recurrent (Rec) tumors, treatments received, and mutation or copy number status. B Cox proportional hazards regression analysis of survival after clinical progression following recurrence for patients whose recurrent tumors had activating mutations in ESR1 (n = 7), mutations in PGR (n = 2), gain of PAQR8 (n = 26), or patients with tumors lacking these three alterations (WT, n = 13). C–F Cox proportional hazards regression analysis of different survival outcomes with respect to PAQR8 gain in primary tumors within the TCGA breast cancer dataset. C Time to recurrence in patients who experienced recurrence across all subtypes controlling for HR/HER2 status (n = 49 WT, 11 PAQR8 gain). Overall survival (n = 378 WT, 72 PAQR8 gain) (D), recurrence-free survival (n = 354 WT, 66 PAQR8 gain) (E), and survival after recurrence (n = 28 WT, 7 PAQR8 gain) (F) in HR +/HER2- patients. G Frequencies of CN gain (red) and CN loss (blue) of PAQR8/Paqr8 in primary and recurrent tumors in humans (left; n = 28 Pri, 66 Rec) and mice (right; n = 159 Pri, 169 Rec). Low-level CNAs (gain and loss) and high-level CNAs (amplification and deletion) are shown as hashed and solid bars, respectively. P values indicate one-sided Fisher’s exact tests. H Paqr8 RNA expression in primary (n = 48) and recurrent (n = 46) tumors across five different GEM models. P values indicate one-sided Wilcoxon rank-sum tests. Median fold-change (FC)

Full size image

Consistent with the above findings, PAQR8 gain in primary breast cancers in The Cancer Genome Atlas (TCGA) was associated with shorter time to recurrence among those patients who recurred across all subtypes (p = 0.039, HR = 2.1) (Fig. 1C). Furthermore, PAQR8 gain in primary tumors was associated with poor overall survival (p = 0.002, HR = 2.5), poor recurrence-free survival (p = 0.071, HR = 2.1), and poor survival following recurrence (p = 0.012, HR = 4.4) among HR+ /HER2– patients (Fig. 1D–F). These findings suggest that PAQR8 CN gain may contribute to tumor recurrence, as well as tumor progression after recurrence, across different breast cancer subtypes.

PAQR8 is upregulated and undergoes CN gain in recurrent tumors across multiple mouse models

To test the hypothesis that PAQR8 CN gain promotes breast cancer recurrence, we employed bitransgenic doxycycline-inducible genetically engineered mouse (GEM) models containing transgenes for both MMTV-rtTA and TetO-driven oncogenes that permit the doxycycline-inducible expression of oncogenes of interest in a mammary epithelial-specific manner [35, 39,40,41,42]. These models faithfully recapitulate key elements of breast cancer progression, including primary tumor formation driven by the doxycycline-dependent expression of oncogenes important in human breast cancer, rapid tumor regression following oncogene downregulation as a manifestation of oncogene addiction, cellular dormancy in residual tumor cells that survive oncogene downregulation, and spontaneous tumor recurrence following a variable latency period [35, 39,40,41,42]. Dormant residual tumor cells isolated from these GEM models express a genetic signature that is strongly associated with recurrence-free survival in breast cancer patients [43], and studies using these GEM models have provided insights into pathways associated with clinical relapse [34, 36, 44, 45].

We first analyzed Paqr8 CN and RNA levels in primary and recurrent tumors arising in five different GEM models in which primary tumorigenesis is driven by Akt (MMTV-rtTA;TetO-Akt1), Her2 (MMTV-rtTA;TetO-Her2), Myc (MMTV-rtTA;TetO-Myc), Wnt1 (MMTV-rtTA;TetO-Wnt1), or Wnt1 in a p53 ± background (MMTV-rtTA;TetO-Wnt1;Trp53+/−) [35, 39,40,41,42, 46, 47]. When compared to our findings in breast cancer patients [3], we found a striking similarity in the pattern of preferential enrichment for Paqr8 CN gain in recurrent, compared to primary, tumors across these GEM models (Fig. 1G). In addition, we found that Paqr8 mRNA levels were markedly upregulated in recurrent compared to primary tumors across all five GEM models (Fig. 1H).

Since recurrent tumors from GEM models arise in the setting of oncogene downregulation, this process is conceptually similar to the development of resistance to targeted therapies. Indeed, pharmacological inhibition of Her2 has been shown to yield similar effects to those observed for genetic downregulation of Her2 [48]. Thus, our finding that Paqr8 undergoes preferential CN gain and is upregulated in recurrent tumors across multiple GEM models, recapitulating the preferential CN gain of PAQR8 in recurrent breast cancers observed in patients, further suggests the hypothesis that Paqr8 promotes tumor recurrence and resistance to therapy.

Paqr8 is both necessary and sufficient to promote efficient breast cancer recurrence

Given the parallel pattern of enrichment for PAQR8 CN gain in recurrent tumors in both humans and mice, along with the observed upregulation of Paqr8 during tumor recurrence in GEM models, we asked whether PAQR8 promotes breast cancer recurrence. To do this, we engineered Her2-dependent primary tumor cells [36, 43,44,45] derived from the MMTV-rtTA;TetO-Her2 inducible GEM model mice [35] to either overexpress Paqr8 or delete Paqr8 using CRISPR-cas9 (Additional file 1, 11: Fig. S1, S11).

Paqr8-overexpressing (Paqr8-OE) or control tumor cells were orthotopically injected into athymic nude (nu/nu) mice maintained on doxycycline. Following primary tumor formation, doxycycline was removed from drinking water, resulting in Her2 downregulation and tumor regression to a non-palpable state (Fig. 2A). Primary tumor formation and regression for Paqr8-OE and control cells occurred with equivalent kinetics (Additional file 2: Fig. S2a). However, monitoring mice maintained off doxycycline revealed that Paqr8-OE tumors recurred significantly faster than controls (HR = 2.4, p = 0.003) (Fig. 2B). This indicates that Paqr8 is sufficient to accelerate the rate of tumor recurrence following Her2 downregulation.

Fig. 2
figure 2

Paqr8 is necessary and sufficient for efficient tumor recurrence and colony formation following Her2 downregulation. A Schematic showing recurrence-free survival assays following orthotopic injection of Her2-dependent primary mouse tumor cells. Kaplan–Meier curves depicting rate of recurrence following Her2 downregulation comparing (B) Her2-dependent primary tumor cells overexpressing Paqr8 (Paqr8-OE) and controls, or (C) Her2-dependent primary tumor cells deleted for Paqr8 using CRISPR-cas9 and two independent guide RNAs (sgPaqr8_gA, sgPaqr8_gB) and controls (sgRosa). Colony formation assays performed in medium containing 10% serum with doxycycline (Her2 ON) or in medium containing 1% serum without doxycycline (Her2 OFF), comparing (D) Her2-dependent primary tumor cells overexpressing Paqr8 and controls, or (E) cells deleted for Paqr8 and sgRosa controls. F, G Bar graphs quantifying the proportion of plated cells that formed colonies under Her2 ON and OFF conditions. H Viable cell counts for BT474-M1 cells in medium containing lapatinib or vehicle control (DMSO)

Full size image

Next, we conducted analogous experiments to determine the effects of Paqr8 deletion (Paqr8-KO) on the rate of tumor recurrence. Two independent guide RNAs against Paqr8 were validated using TIDE PCR [49], which demonstrated that > 90% of cells contained indels likely to result in loss-of-function mutations (Additional file 1: Fig. S1b, c). Cells transduced with either a guide RNA against Paqr8 or sgRosa control were orthotopically injected into nu/nu mice maintained on doxycycline. Primary tumors derived from either Paqr8-KO or sgRosa control cells developed with equivalent kinetics and regressed to a non-palpable state following doxycycline removal and Her2 downregulation (Additional file 2: Fig. S2b). Kaplan–Meier analysis revealed that the rate of recurrence of Paqr8-KO tumors was markedly delayed compared to controls for each of the guides tested (HR = 0.26, p < 0.0001; HR = 0.29, p < 0.0001) (Fig. 2C). Together, these observations indicate that Paqr8 is both necessary and sufficient for efficient mammary tumor recurrence following downregulation of the Her2 pathway.

We next performed colony formation assays using the above Paqr8-OE and Paqr8-KO cells as an in vitro method to evaluate tumor cell outgrowth in the setting of Her2 inhibition. Colony formation in the presence of Her2 expression models primary tumor formation in mice, whereas colony formation in the absence of doxycycline and Her2 expression models Her2-independent tumor recurrence.

Consistent with our in vivo findings, we found no difference in the colony-forming ability of Paqr8-OE or Paqr8-KO cells and their respective controls in the presence of Her2 expression (Fig. 2D, E). In contrast, in the absence of Her2 expression Paqr8-OE cells formed a significantly greater number of colonies than controls (p = 0.003) (Fig. 2F). This parallels the increased rate of recurrence observed for Paqr8-OE tumor cells in mice. Conversely, in the absence of Her2 expression Paqr8-KO cells formed significantly fewer colonies than controls (p = 0.010) (Fig. 2G), paralleling the decreased rate of recurrence observed for Paqr8-KO tumor cells in mice.

To extend these findings to pharmacological inhibition of Her2 in human breast cancer cells, we overexpressed PAQR8 in BT474-M1 cells, a Her2+/ER+ human breast cancer cell line. Consistent with our observations following the genetic downregulation of Her2, PAQR8-OE BT474-M1 cells treated with lapatinib, a small molecule Her2 tyrosine kinase inhibitor, exhibited increased viability compared to controls (Fig. 2H).

Together, the congruent effects of Paqr8 overexpression and deletion in vivo and in vitro reinforce the conclusion that Paqr8 is both necessary and sufficient for tumor recurrence in the setting of Her2 inhibition, either by genetic downregulation or by pharmacological inhibition. In addition, these in vitro findings indicate that the effects of Paqr8 on Her2-independent growth are tumor cell autonomous, do not require stromal or host immune cells, and occur in both human and mouse cells.

Paqr8 confers a competitive advantage on tumor cells following Her2 downregulation

Having demonstrated that Paqr8 is both necessary and sufficient for efficient breast cancer recurrence, we wished to identify the stages of tumor regression, cellular dormancy, and recurrence during which Paqr8 plays a role. To do so, we generated primary tumors by orthotopically injecting a mixture of 20% H2B-eGFP-labeled Her2-GEM model-derived Paqr8-OE cells and 80% H2B-mCherry-labeled vector control cells into nu/nu mice on doxycycline and then withdrew doxycycline to downregulate Her2 and induce tumor regression. We collected primary tumors (PT), dormant residual lesions at 10 or 28 days (D10, D28) following doxycycline withdrawal, and recurrent tumors (RT) arising in the setting of continued Her2 downregulation. These stages roughly correspond to acute tumor regression following Her2 downregulation (PT to D10), early-to-late tumor dormancy (D10 to D28), and tumor cell exit from dormancy and proliferation to yield recurrent tumors (D28 to RT) (Fig. 3A). At each stage, droplet digital PCR (ddPCR) using probes for eGFP and mCherry was used to quantify changes in the ratio of eGFP to mCherry-labeled cells.

Fig. 3
figure 3

Paqr8 confers a competitive advantage to tumor cells following Her2 downregulation. A Experimental schema for in vivo and in vitro competition assays. B eGFP to mCherry ratios determined by ddPCR after injecting a mixture of 80% H2B-eGFP-labeled Paqr8-OE cells and 20% H2B-mCherry-labeled control cells. C eGFP to mCherry ratios determined by ddPCR after injecting a mixture of 20% eGFP-labeled Paqr8-KO and 80% mCherry-labeled sgRosa control cells. D eGFP to mCherry ratios determined by ddPCR after plating 50% H2B-eGFP-labeled Paqr8-OE cells and 50% H2B-mCherry-labeled control cells, following Her2 downregulation at time D0. Data were normalized to a control arm for which 50% H2B-eGFP-labled control cells and 50% H2B-mCherry-labeled control cells were plated in parallel. E eGFP to mCherry ratios determined by ddPCR from plating 50% eGFP-labeled sgPaqr8 cells and 50% mCherry-labeled sgRosa control cells, following Her2 downregulation at time D0. Data were normalized to a control arm for which 50% eGFP-labeled sgRosa cells and 50% mCherry-labeled sgRosa cells were plated in parallel

Full size image

Quantification of the eGFP to mCherry ratio following Her2 downregulation revealed progressive enrichment for eGFP-expressing Paqr8-OE cells across multiple stages of tumor progression, eventually resulting in recurrent tumors with > 90% Paqr8-OE cells (Fig. 3B). The greatest rate of enrichment for Paqr8-OE cells was observed from primary tumors to day 10 of tumor regression (p < 0.0001) (Fig. 3B), during which the bulk of tumor cells die following acute Her2 downregulation. Further selection for Paqr8-OE cells was observed during the dormant phase (D10 to D28) (p < 0.0001) and in recurrent tumors (p = 0.043) (Fig. 3B).

We next performed the converse experiment in which we orthotopically injected a mixture of 80% eGFP-labeled Her2 GEM model-derived Paqr8-KO cells and 20% mCherry-labeled sgRosa cells into nu/nu mice and collected primary tumors, residual lesions at D10 and D28 of dormancy, and recurrent tumors. Quantification of the ratio of eGFP to mCherry-labeled cells by ddPCR revealed that Paqr8-KO cells were progressively selected against, with significant depletion of Paqr8-KO cells observed acutely following therapy (PT to D10) (p = 0.002) (Fig. 3C). Selection against Paqr8-KO cells continued throughout dormancy (D10 to D28) (p = 0.010) and in recurrent tumors (p = 0.016) (Fig. 3C). Together, these results indicate that Paqr8 provides a selective advantage to tumor cells in vivo following acute Her2 downregulation, as well as during dormancy and tumor recurrence.

To further test this hypothesis, we performed in vitro competition assays (Fig. 3A). After plating a 50:50 mixture of eGFP-labeled Paqr8-OE or Paqr8-KO cells and their respective mCherry-labeled controls in the presence of doxycycline, cells were allowed to grow for three days. Cells were then collected prior to Her2 downregulation at Day 0 (D0) to model in vivo primary tumor growth, and at 7, 14, and 28 days (D7, D14, and D28) following doxycycline withdrawal during the period of dormancy. The ratio of eGFP to mCherry-labeled tumor cells was analyzed by ddPCR.

Following Her2 downregulation in vitro, Paqr8-OE cells were selected for, whereas Paqr8-KO cells were selected against, compared to controls (Fig. 3D, E). Significant positive selection for Paqr8-OE (p = 0.029), and negative selection against Paqr8-KO (p = 0.004), tumor cells occurred from D0 to D7, during which time cells undergo apoptosis in response to acute Her2 inhibition. Further selection for Paqr8-OE, and against Paqr8-KO, tumor cells was observed from D7 to D28 of the dormancy period. Thus, in vitro competition assays recapitulate results from in vivo studies in mice.

Together, these in vivo and in vitro findings consistently and concordantly indicate that Paqr8 confers a selective advantage on tumor cells following Her2 downregulation, particularly during the initial phase of response to therapy.

Paqr8 promotes cell survival by reducing apoptosis following Her2 downregulation

The competitive advantage exhibited by Paqr8-OE, and competitive disadvantage exhibited by Paqr8-KO, tumor cells following Her2 downregulation could potentially result from Paqr8-mediated differences in cell survival, proliferation, or both. We therefore performed immunofluorescence for markers for apoptosis (cleaved caspase-3), cell cycle (Ki67), and S-phase (EdU) in Paqr8-OE and Paqr8-KO tumor cells following Her2 downregulation in vivo and in vitro. In vivo, Paqr8-OE cells exhibited significantly reduced levels of staining for cleaved caspase-3 compared to controls 72 h after Her2 downregulation (p = 0.008) (Fig. 4A, C), whereas Paqr8-KO cells exhibited significantly increased levels of cleaved caspase-3 staining compared to controls (p = 0.001) (Fig. 4B, D). Similarly, 72 h after Her2 downregulation in vitro, Paqr8-OE cells exhibited significantly lower levels of cleaved caspase-3 compared to controls (p = 0.009) and Paqr8-KO cells exhibited significantly higher levels of cleaved caspase-3 compared to controls (p = 0.015) (Fig. 4G, H).

Fig. 4
figure 4

Paqr8 enhances cell survival without affecting proliferation following Her2 downregulation. Regressing tumors from nu/nu mice bearing Paqr8-OE or Paqr8-KO primary orthotopic tumors at three days (D3) following Her2 downregulation were stained by immunofluorescence for cleaved caspase-3 (cc3). Representative images are shown (A, B), and the proportions of eGFP + cells that were cc3 + were quantified (C, D). D3 regressing tumors were also stained for EdU and Ki67, and the proportions of eGFP + cells that were EdU + or Ki67 + were quantified (E, F). Paqr8-OE (G, I) or Paqr8-KO (H, J) cells were cultured in medium containing 1% serum without doxycycline (Her2 OFF) for 72 h. Cells were incubated with 10 mM EdU for 2 h prior to fixation, permeabilization, and staining by immunofluorescence. G, H Quantification of the proportion of eGFP + cells that were cc3+. I, J Quantification of the proportion of eGFP + cells that were EdU + or Ki67+

Full size image

No significant differences were observed in staining for EdU or Ki67 between Paqr8-OE and Paqr8-KO cells and their respective controls either in vivo (Fig. 4E, F; Additional file 3: Fig. S3) or in vitro (Fig. 4I, J; Additional file 4: Fig. S4). In addition, in the presence of Her2 expression, both Paqr8-OE and Paqr8-KO tumor cells exhibited levels of staining for apoptotic and proliferative markers that were similar to their respective controls (Additional file 5: Fig. S5).

In aggregate, these data indicate that Paqr8 promotes cell survival following Her2 downregulation without exerting a significant impact on cell proliferation. This, in turn, suggests that the competitive advantage conferred on tumor cells by Paqr8 following Her2 downregulation is principally mediated by effects of Paqr8 on tumor cell survival.

PAQR8 promotes survival of ER+ tumor cells following estrogen pathway inhibition in vitro

The finding that PAQR8 CN gain was mutually exclusive with activating ESR1 mutations among patients treated with anti-estrogen therapy (Fig. 1A) raised the intriguing hypothesis that PAQR8 might play a role in promoting resistance to anti-estrogen therapy in a manner that is in some way redundant with ESR1 mutation [3]. To test this hypothesis, we overexpressed PAQR8 in MCF7 cells, an ER+ human breast cancer cell line with low endogenous expression of PAQR8. Under complete growth conditions, comprised of 10% fetal bovine serum (FBS) in base medium containing the estrogenic pH indicator phenol red (PhR) [50], PAQR8-OE MCF7 cells exhibited a modestly increased ability to form colonies (Fig. 5A). However, under conditions of estrogen deprivation achieved using charcoal-stripped serum (csFBS) and PhR-free medium, the magnitude of this PAQR8-dependent enhancement of colony-forming capacity was increased (p = 0.030) (Fig. 5A, B; Additional file 6: Fig. S6a).

Fig. 5
figure 5

Paqr8 promotes ER+ breast cancer cell survival following E2 pathway inhibition. A Representative images of MCF7 colony formation assays performed in growth medium (+ PhR FBS), E2-deprived medium (–PhR csFBS), or E2-deprived medium supplemented with 1 nM E2 (–PhR csFBS + E2). Proportion of cells plated that formed colonies in –PhR csFBS (B) or –PhR csFBS + E2 medium (C), normalized to + PhR FBS medium. D Viable cell count of BT474-M1 cells in –PhR csFBS or –PhR csFBS + E2 medium, normalized to + PhR FBS medium. E Representative images of MCF7 colony formation assays performed in the presence of increasing concentrations of fulvestrant or vehicle control (DMSO), and quantification (F). G Representative images of immunofluorescence staining for cleaved caspase-3 (cc3) in –PhR csFBS or + PhR FBS medium, and quantification (H). I Percentage of eGFP+ cells that were EdU+ or Ki67+ following 2 h of 10 mM EdU labeling. (J) Time to first palpation of MCF7 tumors forming in NSG mice without E2 pellet supplementation. K Representative cc3 staining in primary tumor tissue sections, and quantification (L). Sections were also stained for EdU and Ki67, and the percentages of eGFP+ cells that were EdU+ or Ki67+ were quantified (M)

Full size image

Since charcoal-stripped serum lacks not only estrogen but also other lipid-soluble constituents, we reintroduced 17β-estradiol (E2) to csFBS PhR-free medium to determine whether the observed effects were solely due to estrogen removal. Indeed, addition of 1 nM E2 to csFBS PhR-free medium abrogated the increased colony formation conferred by PAQR8 overexpression under estrogen-deprived conditions (Fig. 5A, C; Additional file 6: Fig. S6a).

Consistent with our findings in MCF7 cells, PAQR8 overexpression in Her2+/ER+ BT474-M1 cells also conferred resistance to estrogen deprivation in csFBS PhR-free medium (p = 0.003) that was rescued by the addition of estradiol (Fig. 5D; Additional file 6: Fig. S6b).

Furthermore, we found that MCF7 PAQR8-OE cells exhibited increased colony formation in the presence of fulvestrant, a selective estrogen receptor degrader (Fig. 5E, F; Additional file 6: Fig. S6c). Overall, these findings indicate that PAQR8 confers resistance to multiple forms of estrogen receptor pathway inhibition.

To evaluate whether the enhanced colony-forming capacity of PAQR8-OE MCF7 cells under E2-deprived media conditions was due to cell survival, cell proliferation, or both, we performed immunofluorescence for cleaved caspase-3, EdU, and Ki67 in cells cultured under estrogen-deprived or estrogen-replete conditions. PAQR8-OE cells displayed significantly lower levels of cleaved caspase-3 staining compared to controls under E2-deprived conditions (p = 0.046), but not under E2-replete conditions (Fig. 5G, H). In contrast, the percentage of cells that were EdU+ or Ki67+ did not differ significantly between MCF7 PAQR8-OE cells and controls under either condition (Fig. 5I; Additional file 7: Fig. S7).

Consistent with the conclusion from the above findings that PAQR8 promotes cell survival in the setting of therapy targeting either Her2 or ER, rather than mediating an effect of estrogen per se, we found that addition of either estradiol or progesterone to ER-negative Her2-dependent primary mouse cells in charcoal-stripped serum had no effect on their viability, irrespective of PAQR8 overexpression or deletion (Additional file 8: Fig. S8).

PAQR8 promotes survival of ER+ tumor cells following estrogen deprivation in vivo

To determine whether PAQR8-dependent effects on cell survival observed under E2-deprived media conditions in vitro were recapitulated in vivo, we orthotopically injected MCF7 PAQR8-OE or control cells into NOD SCID gamma (NSG) mice. MCF7 cells have been shown to form tumors in NSG mice without the need for E2 pellet supplementation [51]. NSG mice also exhibit low endogenous levels of E2 compared to human beings [52], hence modeling conditions of estrogen deprivation.

Following orthotopic injection, mice were monitored for primary tumor formation. MCF7 cells overexpressing PAQR8 formed detectable tumors significantly earlier than vector controls (HR = 1.4, p = 0.044) (Fig. 5J). When tumors reached 8 × 8 mm, mice were sacrificed, and tumors were fixed, sectioned, and stained by immunofluorescence for apoptotic and proliferative markers. We found that PAQR8-OE tumors displayed significantly reduced levels of cleaved caspase-3 compared to control tumors of similar size (p = 0.005) (Fig. 5K, L). In contrast, no significant difference was observed between PAQR8-OE tumors and controls with respect to the percentage of tumor cells that were EdU+ or Ki67+ (Fig. 5M; Additional file 9: Fig. S9). Thus, consistent with in vitro findings under estrogen-deprived conditions, PAQR8 also confers a survival advantage in response to estrogen deprivation in vivo.

PAQR8 confers resistance to chemotherapies

As noted above, PAQR8 CN gain in recurrent breast cancers was not restricted to hormone receptor-positive tumors and occurred with equal frequency in recurrent metastatic tumors in patients treated with other forms of therapy, including chemotherapy and anti-Her2 therapy [3]. This suggested the possibility that PAQR8 might promote resistance to therapies beyond those targeting ER or Her2.

To investigate this hypothesis, we tested the effects of PAQR8 overexpression or PAQR8 deletion on the response to treatment with doxorubicin or docetaxel, chemotherapeutic agents commonly used in treating breast cancer patients. We first used CRISPR-cas9 to delete PAQR8 in the triple-negative human breast cancer cell line SUM159, which expresses high endogenous levels of PAQR8. Colony formation assays were then performed in which PAQR8-KO and control SUM159 cells were treated with doxorubicin or docetaxel. This revealed that PAQR8-KO SUM159 cells exhibited increased sensitivity to both doxorubicin and docetaxel compared to controls (Fig. 6A, B; Additional file 10: Fig. S10a, b).

Fig. 6
figure 6

PAQR8 promotes resistance to chemotherapy. A Representative images of colony formation assays of SUM159 cells in media containing doxorubicin, docetaxel, or vehicle control (DMSO). B Proportion of plated cells that formed colonies in the presence of doxorubicin or docetaxel, normalized to DMSO control. C Representative images of colony formation assays of MCF7 cells in media containing doxorubicin, docetaxel, or vehicle control (DMSO). D Proportion of plated cells that formed colonies in the presence of doxorubicin or docetaxel, normalized to DMSO control. E Viable cell counts of BT474-M1 cells in the presence of doxorubicin or docetaxel, normalized to DMSO control

Full size image

Consistent with this result, MCF7 cells overexpressing PAQR8 exhibited increased colony formation compared to controls in the presence of either doxorubicin or docetaxel (Fig. 6C, D; Additional file 10: Fig. S10c). Similarly, BT474-M1 cells overexpressing PAQR8 exhibited increased viability compared to controls in the presence of either doxorubicin or docetaxel (Fig. 6e; Additional file 10: Fig. S10d). Together, these findings suggest that PAQR8 promotes breast cancer cell resistance to chemotherapy.

Pro-survival effects of PAQR8 are mediated by a Gi-dependent reduction in cAMP

Endogenous PAQR8 and its related mPR family member PAQR7 have been reported to co-immunoprecipitate with Gi proteins in human myometrial cells [11]. Consistent with Gi protein-mediated effects, Paqr7 siRNA knockdown abrogated the progesterone-induced reduction in cAMP levels in mouse neuronal cells [18]. In contrast, siRNA knockdown of Paqr8 in mouse neuronal cells did not affect progesterone-induced changes in cAMP levels [18]. Hence, the question of whether PAQR8 functions by coupling to Gi proteins remains unclear.

To address this, we measured cAMP levels in mouse Paqr8-OE and Paqr8-KO Her2-dependent primary tumor cells following acute Her2 downregulation, conditions under which Paqr8 exerts a pro-survival effect. Following Her2 downregulation for 72 h, Paqr8 overexpression reduced basal, as well as forskolin-stimulated, levels of cAMP compared to control cells (p = 2.72e-05, p = 0.001) (Fig. 7A). Conversely, under the same conditions, Paqr8-KO cells exhibited increased basal, as well as forskolin-stimulated, levels of cAMP compared to controls (p = 0.027, p = 0.001) (Fig. 7B). These data suggest that Paqr8 reduces cAMP levels in the setting of Her2 inhibition.

Fig. 7
figure 7

Cell survival effects of Paqr8 are dependent on Gi protein-mediated reductions in cAMP. A, B Intracellular cAMP measurements of Her2-dependent primary mouse tumor cells following 72 h of Her2 downregulation, with or without addition of 1μM forskolin (Fsk) for 15 min prior to collection, and with or without 12-h preincubation with 100 ng/ml pertussis toxin (PTX). C, D Viable cell counts of Her2-dependent primary tumor cells at 72 h following Her2 withdrawal, in the presence or absence of 100 ng/ml PTX. E, F Percentage of eGFP+ cells that were cleaved caspase-3 + by immunofluorescence staining of Her2-dependent primary cells cultured for 72 h after Her2 downregulation, in the presence or absence of 100 ng/ml PTX

Full size image

To determine whether the observed changes in cAMP levels were mediated by a Gi protein-coupled receptor, we preincubated Paqr8-OE or Paqr8-KO tumor cells with pertussis toxin (PTX) prior to measuring forskolin-stimulated levels of cAMP. PTX preincubation for 12 h abrogated Paqr8-dependent increases in cAMP in Paqr8-KO cells stimulated with forskolin and markedly reduced Paqr8-dependent decreases in cAMP in Paqr8-OE cells, compared to controls (Fig. 7A, B). This indicates that Paqr8-mediated changes in cAMP levels are dependent on a Gi protein-coupled receptor.

Next, we investigated whether the pro-survival effects of Paqr8 are also dependent on its Gi protein-coupled activity. Consistent with our prior results, we observed an increase in viable Paqr8-OE tumor cells, as well as a decrease in viable Paqr8-KO tumor cells, compared to controls following Her2 downregulation for 72 h (Fig. 7C, D). Notably, co-incubation with PTX abrogated differences in viable cell number between Paqr8-OE and Paqr8-KO cells and their respective controls following Her2 downregulation (Fig. 7C, D).

To confirm and extend this finding, we performed immunofluorescence for cleaved caspase-3 following Her2 downregulation in the presence of PTX. As before, Paqr8 overexpression resulted in a reduced percentage of cleaved caspase-3-positive cells (p = 0.025), whereas Paqr8 deletion resulted in an increased percentage of cleaved caspase-3-positive cells (p = 0.039), 72 h after Her2 downregulation (Fig. 7E, F). In contrast, no differences in cleaved caspase-3 staining were observed between Paqr8-OE cells and controls, or between Paqr8-KO cells and controls, in the presence of PTX (Fig. 7E, F). Together, these studies indicate that the pro-survival effects conferred by Paqr8 in the setting of acute Her2 inhibition are dependent on a reduction in cAMP levels mediated by a Gi protein-coupled receptor.

Paqr8 alters the balance of ceramides and sphingosine-1-phosphate

Beyond the hypothesis that PAQR8 functions as a GPCR, it has been suggested that PAQR8 might function as an alkaline ceramidase, or possibly as both a ceramidase and a GPCR [22]. Alkaline ceramidases convert ceramides to sphingosine, which in turn can be phosphorylated by sphingosine kinase to produce sphingosine-1-phosphate (S1P) [53]. While ceramides promote apoptosis, S1P can suppress apoptosis, in part by counterbalancing pro-apoptotic effects of ceramides [54]. Thus, the interconversion between ceramides and S1P, referred to as the ceramide:S1P ‘rheostat’, plays an important role in determining the cellular balance between survival and death [55].

To begin to query whether PAQR8 might function as a ceramidase, we analyzed the sphingolipidome of Paqr8-OE and Paqr8-KO Her2-dependent primary tumor cells 72 h after Her2 downregulation using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Paqr8-OE cells exhibited significantly lower levels of the most abundant ceramides Cer(16:0, 18:0, 20:0, 22:0, 24:0, and 24:1) (Fig. 8A). Conversely, Paqr8-KO cells exhibited significantly higher levels of these same ceramide species compared to controls (Fig. 8B). These data are consistent with increased ceramidase activity in Paqr8 expressing cells, which would hydrolyze and thereby reduce ceramide levels within cells.

Fig. 8
figure 8

Paqr8 decreases ceramide levels and increases S1P levels. A, B Levels of ceramides Cer(d18:1_16:0, 18:0, 20:0, 22:0, 24:0, 24:1) and sphingosine (SPH) in Her2-dependent primary mouse tumor cells quantified by LC-HRMS 72 h after Her2 downregulation. C, D Sphingosine-1-phosphate (S1P) levels quantified in the same cells by LC-HRMS 72 h after Her2 downregulation

Full size image

Interestingly, significant changes in levels of sphingosine, the product of ceramide hydrolysis, were not observed in either Paqr8-OE or Paqr8-KO cells compared to controls (Fig. 8A, B). Sphingosine can be phosphorylated by sphingosine kinases to form sphingosine-1-phosphate (S1P), which counterbalances the pro-apoptotic effects of ceramides and sphingosine. Consistent with this mode of regulation, cellular S1P levels were significantly increased in Paqr8-OE cells compared to controls (p = 0.036) (Fig. 8C). A significant difference in S1P levels between Paqr8-KO cells compared to sgRosa controls was not observed (Fig. 8D). As S1P levels are generally 100–1000-fold lower than ceramide levels, this finding may be attributable to limitations in assay sensitivity.

Together, our findings indicate that Paqr8 expression decreases ceramide levels, increases S1P levels, and thereby decreases the ceramide:S1P ratio, which would be anticipated to favor cell survival. Further, the observed Paqr8-dependent decreases in ceramides are consistent with a model in which Paqr8 can function as an alkaline ceramidase, and further suggest that a Paqr8-mediated reduction in the ratio of ceramide:S1P may underlie its pro-survival effects.

Discussion

Although therapy-resistant recurrent disease is principally responsible for breast cancer mortality, mechanisms of resistance have been identified in only a minority of cases. This is exemplified by resistance to anti-estrogen therapies, which ultimately develops in most, if not all, metastatic breast cancers treated with such agents. While ESR1 activating mutations, MAPK pathway alterations, and mutations in MYC and other transcription factors are known mechanisms of resistance in hormone receptor-positive breast cancer, it has been estimated that these mechanisms together account for only 40% of endocrine resistance [56]. Elucidating the, as yet, ‘occult’ mechanisms that may account for ~ 60% of endocrine therapy resistance is therefore a critical priority.

We identified PAQR8 CN gain as a common focal CN alteration that preferentially occurs in therapy-resistant recurrent metastatic tumors in breast cancer patients [3]. Our findings that PAQR8 CN gain was mutually exclusive with activating ESR1 mutations in patients treated with anti-estrogen therapy, and that PAQR8 CN gain occurred with equal frequencies in patients who received anti-estrogen therapy and in those treated with chemotherapy or agents targeting Her2 [3], suggested the possibility that PAQR8 might confer resistance to multiple forms of therapy. This hypothesis is further supported by our findings here that Paqr8 is spontaneously upregulated and frequently undergoes CN gain in recurrent mammary tumors in mice arising from Her2, Akt, Myc, and Wnt1-induced primary tumors subjected to oncogene downregulation, which is a genetic surrogate for targeted therapy.

Consistent with our findings of frequent PAQR8 CN gain in therapy-resistant recurrent tumors in breast cancer patients and mouse models, we now provide the first in vivo evidence that PAQR8 plays a functional role in cancer and does so through its ability to confer a survival advantage on tumor cells subjected to different forms of therapy. In particular, we demonstrated that PAQR8 is both necessary and sufficient to promote efficient mammary tumor recurrence following Her2 inhibition and that PAQR8 facilitates the outgrowth of orthotopically implanted ER + tumor cells under conditions of estrogen deprivation. These in vivo tumor-promoting effects of PAQR8 were attributable to its ability to promote tumor cell survival in response to Her2 downregulation or pharmacologic inhibition, estrogen deprivation or anti-estrogen therapy, or treatment with the chemotherapeutic agents doxorubicin or docetaxel. Together, these observations reveal a role for PAQR8 in mediating resistance to multiple types of therapy, which in turn can promote tumor recurrence.

While ESR1 mutations are the most common mechanism of endocrine resistance identified to date, they occur in only ~20% of treatment-resistant tumors and are generally limited to patients treated with aromatase inhibitors [7, 8, 57, 58]. Thus, even after considering mutations in ESR1 and other known mechanisms, nearly 60% of endocrine resistance is unexplained [56]. Accordingly, our observations that PAQR8 CN gain occurs in > 50% of patients treated with anti-estrogen therapies, as well as in > 50% of patients treated with chemotherapy or Her2-targeted therapies [3], suggest the important possibility that PAQR8 upregulation may account for a substantial fraction of therapy resistance, including endocrine therapy resistance, and in doing so may facilitate tumor recurrence across multiple subtypes of breast cancer.

PAQR8 has been reported to function as a membrane progesterone receptor that conveys rapid non-genomic effects of progesterone signaling. Our findings presented here, however, indicate that PAQR8 can function in the absence of progesterone. Indeed, in ER/PR-negative Her2-dependent mouse primary tumor cells, the addition of progesterone to charcoal-stripped serum, which is depleted of lipid-soluble hormones such as progesterone, did not affect the ability of Paqr8 overexpression to enhance, or Paqr8 deletion to impair, cell viability following Her2 downregulation. Moreover, both the increased colony-forming ability and survival advantage that we observed for PAQR8 overexpressing MCF7 cells were enhanced, not diminished, in charcoal-stripped serum.

Our findings that PAQR8 can function independently of progesterone are consistent with a study in yeast that employed a heterologous reporter construct containing a portion of the FET3 promoter that is repressed by the yeast PAQR protein Izh2p. In this system, human PAQR7 required progesterone for repression of FET3 reporter activity, whereas PAQR8 repressed this construct in the absence of progesterone, as did several other PAQR family members [19]. Thus, the extent to which progesterone-dependent and independent effects of PAQR8 may be context-dependent, or may differ from those of PAQR7, remains to be clarified.

Based on the presence of three motifs conserved among alkaline ceramidases, PAQR8 has been hypothesized to possess ceramidase activity [22]. Indeed, PAQR1 and PAQR2 (i.e., adiponectin receptors 1 and 2) have been reported to possess low levels of basal ceramidase activity [25]. However, evidence in the literature that mPRs in eukaryotic cells possess ceramidase activity is lacking [17]. We provide the first functional evidence to support the hypothesis that PAQR8 may function as a ceramidase by demonstrating that knockdown of endogenous PAQR8 increases ceramide levels, whereas PAQR8 overexpression decreases ceramide levels while increasing levels of S1P.

Ceramides are established mediators of apoptosis and can act via a diverse array of mechanisms, including inhibition of Bcl-2, Bcl-xL the PI3K/AKT pathway, and pathways involving hnRNPA1, a regulator of alternative splicing [59,60,61]. Conversely, S1P is an inhibitor of ceramide-mediated apoptosis [62]. Thus, PAQR8 function as a ceramidase would be consistent with the pro-survival effects that we observe. Nevertheless, these PAQR8-dependent changes in sphingolipidome composition could be directly mediated by PAQR8 or by activation of a downstream ceramidase. Hence, the mechanisms by which PAQR8 affects sphingolipid metabolism warrant further investigation.

At the molecular level, we determined that the pro-survival effects of PAQR8 were mediated by a Gi protein-dependent reduction in cAMP levels that was abrogated by treatment with pertussis toxin. Gi protein activation can mediate anti-apoptotic effects via activation of MAPK or PI3K/AKT pathways, resulting in the inhibition of caspases and pro-apoptotic proteins such as BAX and BAD [63,64,65]. Indeed, PAQR8 and Gi have been reported to co-immunoprecipitate [11] and to be located within 40 nm of each other as assessed by an in situ proximity ligation assay [17], as would be anticipated if PAQR8 functions as a GPCR.

An alternative model to explain our findings would be if PAQR8 functions as a ceramidase that facilitates conversion of ceramides to the downstream sphingosine metabolite, S1P. S1P binding to S1P receptors, which are GPCRs [66], could in turn activate Gi proteins, resulting in anti-apoptotic effects mediated by ERK1/2 activation or suppression of BAX expression [67,68,69]. An additional possibility is that PAQR8 may function as both a ceramidase and a GPCR [22]. In this regard, recent computational predictions suggest that PAQR8 may possess eight transmembrane domains [70, 71], unlike the 7-transmembrane structure of ceramidases and GPCRs, such that the additional C-terminal transmembrane domain could potentially couple to a Gi protein. However, no experimental evidence to date supports such a structure. Further investigation will be required to clarify the direct or indirect nature of PAQR8-dependent effects on ceramide levels as well as Gi protein activation.

Conclusions

In aggregate, our studies provide in vivo evidence that PAQR8 plays a functional role in cancer, implicate PAQR8, ceramide metabolism, and cAMP in breast cancer recurrence, and identify a novel mechanism of resistance to multiple antineoplastic therapies. In addition, the possibility that PAQR8 may contribute to a substantial fraction of treatment resistance in breast cancer patients nominates this poorly understood molecule for further study as a potential therapeutic target to reverse therapy resistance and improve outcomes for breast cancer patients.

Availability of data and materials

The datasets used in the current study are available from the corresponding author on reasonable request.

Abbreviations

CN:

Copy number

cAMP:

Cyclic adenosine monophosphate

ER:

Estrogen receptor

mPR:

Membrane progesterone receptor

PAQR:

Progestin and adipoQ receptor

GPCR:

G protein-coupled receptor

Gi :

Inhibitory G protein

PTX:

Pertussis toxin

TCGA:

The Cancer Genome Atlas

GEM:

Genetically engineered mouse

OE:

Overexpression

KO:

Knock-out

nu/nu :

Athymic nude

PT:

Primary tumor

RT:

Recurrent tumor

cc3:

Cleaved caspase-3

EdU:

5-Ethynyl-2′-deoxyuridine

FBS:

Fetal bovine serum

csFBS:

Charcoal-stripped fetal bovine serum

PhR:

Phenol red

E2:

17β-Estradiol

NSG :

NOD SCID gamma

S1P:

Sphingosine-1-phosphate

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  Google Scholar 

  2. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.

    Article  Google Scholar 

  3. Paul MR, Pan TC, Pant DK, Shih NNC, Chen Y, Harvey KL, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest. 2020;140:4252–65.

    Google Scholar 

  4. Li J, Liu J, Li P, Mao X, Li W, Yang J, et al. Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion. J Exp Clin Cancer Res. 2014;33:1–13.

    Article  Google Scholar 

  5. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Article  CAS  Google Scholar 

  6. Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R, et al. PTK6 regulates growth and survival of endocrine therapy resistant ER+ breast cancer cells. NPJ Breast Cancer. 2017;3:1–6.

    Article  CAS  Google Scholar 

  7. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–45.

    Article  CAS  Google Scholar 

  8. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51.

    Article  CAS  Google Scholar 

  9. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA. 2003;100:2168–70.

    Article  Google Scholar 

  10. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA. 2003;100:2237–42.

    Article  CAS  Google Scholar 

  11. Karteris E, Zervou S, Pang Y, Dong J, Hillhouse EW, Randeva HS, et al. Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: Potential role in functional progesterone withdrawal at term. Mol Endocrinol. 2006;20:1519–34.

    Article  CAS  Google Scholar 

  12. Dressing GE, Thomas P. Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids. 2007;72:111–6.

    Article  CAS  Google Scholar 

  13. Charles NJ, Thomas P, Lange CA. Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: Implications for progesterone-induced signaling events. Horm Cancer. 2010;1:167–76.

    Article  CAS  Google Scholar 

  14. Krietsch T, Fernandes MS, Kero J, Lösel R, Heyens M, Lam EWF, et al. Human homologs of the putative G protein-coupled membrane progestin receptors (mPRα, β, and γ) localize to the endoplasmic reticulum and are not activated by progesterone. Mol Endocrinol. 2006;20:3146–64.

    Article  CAS  Google Scholar 

  15. Kasubuchi M, Watanabe K, Hirano K, Inoue D, Li X, Terasawa K, et al. Membrane progesterone receptor beta (mPRβ/Paqr8) promotes progesterone-dependent neurite outgrowth in PC12 neuronal cells via non-G protein-coupled receptor (GPCR) signaling. Sci Rep. 2017;7:1–12.

    Article  CAS  Google Scholar 

  16. Smith JL, Kupchak BR, Garitaonandia I, Hoang LK, Andrew S, Regalla LM, et al. Heterologous expression of human mPRα, mPRβ and mPRγ in yeast confirms their ability to function as membrane progesterone receptors. Steroids. 2008;73(11):1160–73.

    Article  Google Scholar 

  17. Kelder J, Pang Y, Dong J, Schaftenaar G, Thomas P. Molecular modeling, mutational analysis and steroid specificity of the ligand binding pocket of mPRα (PAQR7): shared ligand binding with AdipoR1 and its structural basis. J Steroid Biochem Mol Biol. 2022;219:106082.

    Article  CAS  Google Scholar 

  18. Sleiter N, Pang Y, Park C, Horton TH, Dong J, Thomas P, et al. Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release. Endocrinology. 2009;150:3833–44.

    Article  CAS  Google Scholar 

  19. Garitaonandia I, Smith JL, Kupchak BR, Lyons TJ. Adiponectin identified as an agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal Transduct. 2009;29:67–73.

    Article  CAS  Google Scholar 

  20. Hanna R, Pang Y, Thomas P, Zhu Y. Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors α and β in transfected cells. J Endocrinol. 2006;190:247–60.

    Article  CAS  Google Scholar 

  21. Kurose H, Katada T, Amano T, Ui M. Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via α-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells. J Biol Chem. 1983;258:4870–5.

    Article  CAS  Google Scholar 

  22. Moussatche P, Lyons TJ. Non-genomic progesterone signalling and its non-canonical receptor. Biochem Soc Trans. 2012;40:200–4.

    Article  CAS  Google Scholar 

  23. Villa NY, Kupchak BR, Garitaonandia I, Smith JL, Alonso E, Alford C, et al. Sphingolipids function as downstream effectors of a fungal PAQF. Mol Pharmacol. 2009;75:866–75.

    Article  CAS  Google Scholar 

  24. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55–63.

    Article  CAS  Google Scholar 

  25. Vasiliauskaité-Brooks I, Sounier R, Rochaix P, Bellot G, Fortier M, Hoh F, et al. Structural insights into adiponectin receptors suggest ceramidase activity. Nature. 2017;544:120–3.

    Article  Google Scholar 

  26. Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, et al. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Res Treat. 2017;164:627–38.

    Article  CAS  Google Scholar 

  27. Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375:1109–12.

    Article  Google Scholar 

  28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.

    Article  CAS  Google Scholar 

  29. Scheinin I, Sie D, Bengtsson H, Van De Wiel MA, Olshen AB, Van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014;24:2022–32.

    Article  CAS  Google Scholar 

  30. Poell JB, Mendeville M, Sie D, Brink A, Brakenhoff RH, Ylstra B. ACE: Absolute copy number estimation from low-coverage whole-genome sequencing data. Bioinformatics. 2019;35:2847–9.

    Article  CAS  Google Scholar 

  31. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.

    Article  CAS  Google Scholar 

  32. Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.

    Article  CAS  Google Scholar 

  33. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1–21.

    Article  Google Scholar 

  34. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8:197–209.

    Article  CAS  Google Scholar 

  35. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2:451–61.

    Article  CAS  Google Scholar 

  36. Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, et al. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015;125:2484–96.

    Article  Google Scholar 

  37. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:1–7.

    Article  CAS  Google Scholar 

  38. Wang D, Xu P, Mesaros C. Analytical considerations for reducing the matrix effect for the sphingolipidome quantification in whole blood. Bioanalysis. 2021;13:1037–49.

    Article  CAS  Google Scholar 

  39. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001;7:235–9.

    Article  Google Scholar 

  40. Gunther EJ, Belka GK, Wertheim GBW, Wang J, Hartman JL, Boxer RB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 2002;16:283–92.

    Article  CAS  Google Scholar 

  41. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003;17:488–501.

    Article  CAS  Google Scholar 

  42. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6:577–86.

    Article  CAS  Google Scholar 

  43. Ruth JR, Pant DK, Pan TC, Seidel HE, Baksh SC, Keister BA, et al. Cellular dormancy in minimal residual disease following targeted therapy. Breast Cancer Res. 2021;23:1–23.

    Article  Google Scholar 

  44. Alvarez JV, Pan TC, Ruth J, Feng Y, Zhou A, Pant D, et al. Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. Cancer Cell. 2013;24:30–44.

    Article  CAS  Google Scholar 

  45. Feng Y, Pan TC, Pant DK, Chakrabarti KR, Alvarez JV, Ruth JR, et al. SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. Cancer Discov. 2014;4:790–803.

    Article  CAS  Google Scholar 

  46. Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, Alavi A, et al. Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. Cancer Res. 2014;74:7583–98.

    Article  CAS  Google Scholar 

  47. Boxer RB, Stairs DB, Dugan KD, Notarfrancesco KL, Portocarrero CPP, Keister BA, et al. Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab. 2006;4:475–90.

    Article  CAS  Google Scholar 

  48. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29:255–69.

    Article  CAS  Google Scholar 

  49. Brinkman EK, Chen T, Amendola M, Van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42(22):e168.

    Article  Google Scholar 

  50. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA. 1986;83:2496–500.

    Article  CAS  Google Scholar 

  51. Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, et al. A new mouse model for the study of human breast cancer metastasis. PLoS One. 2012;7(10):e47995.

    Article  CAS  Google Scholar 

  52. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol. 2010;121:611–8.

    Article  CAS  Google Scholar 

  53. Olivera A, Rosenthal J, Spiegel S. Sphingosine kinase from Swiss 3T3 fibroblasts: a convenient assay for the measurement of intracellular levels of free sphingoid bases. Anal Biochem. 1994;223:306–12.

    Article  CAS  Google Scholar 

  54. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800–3.

    Article  CAS  Google Scholar 

  55. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta Mol Cell Biol Lipids. 2002;1585:193–201.

    Article  CAS  Google Scholar 

  56. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427-438.e6.

    Article  CAS  Google Scholar 

  57. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, et al. D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–64.

    Article  CAS  Google Scholar 

  58. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757–67.

    Article  CAS  Google Scholar 

  59. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem. 1998;273:30419–26.

    Article  CAS  Google Scholar 

  60. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem. 1999;274:20296–300.

    Article  CAS  Google Scholar 

  61. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta Mol Cell Biol Lipids. 2002;1585:114–25.

    Article  CAS  Google Scholar 

  62. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993;365:557–60.

    Article  CAS  Google Scholar 

  63. Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA, et al. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ. 2004;11:1287–98.

    Article  CAS  Google Scholar 

  64. Fang X, Yu S, Pushin RLA, Lu Y, Furui T, Penn LZ, et al. G i -protein-mediated activation of mitogen-activated protein kinase. 2000;143:135–43.

  65. Sautin YY, Crawford JM, Svetlov SI. Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol. 2001;281(6):50–6.

    Article  Google Scholar 

  66. Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MBA. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem. 2013;82:637–62.

    Article  CAS  Google Scholar 

  67. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol. 1999;162:2049–56.

    Article  CAS  Google Scholar 

  68. An S, Bleu T, Zheng Y. Transduction of intracellular calcium signals through G protein- mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. Mol Pharmacol. 1999;55:787–94.

    CAS  Google Scholar 

  69. An S, Zheng Y, Bleu T. Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J Biol Chem. 2000;275:288–96.

    Article  CAS  Google Scholar 

  70. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.

    Article  CAS  Google Scholar 

  71. Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Žídek A, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596:590–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Junwei Shi and members of his laboratory for consultation on CRISPR-cas9 and cloning techniques. We thank Jianping Wang for technical assistance in embedding and sectioning in vivo tissues, as well as current and past members of the Chodosh laboratory for productive discussions surrounding the topics presented here.

Funding

This work was supported in part by philanthropy from Rhoda Polly Danziger and Michael Danziger, and grants from the NIH, the Breast Cancer Research Foundation, and DOD W81XWH-22–1-0312 to LAC, and F30CA253989 to SC.

Author information

Authors and Affiliations

  1. Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Room 614 BRB II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-6160, USA

    Saisai Chen, Matt R. Paul, Christopher J. Sterner, George K. Belka, Amulya Sreekumar, Tien-chi Pan, Dhruv K. Pant & Lewis A. Chodosh

  2. 2-PREVENT Translational Center of Excellence, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Matt R. Paul, Christopher J. Sterner, George K. Belka, Tien-chi Pan, Dhruv K. Pant, Igor Makhlin, Angela DeMichele & Lewis A. Chodosh

  3. Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Saisai Chen, Matt R. Paul, Christopher J. Sterner, George K. Belka, Amulya Sreekumar, Tien-chi Pan, Dhruv K. Pant & Lewis A. Chodosh

  4. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Saisai Chen, Igor Makhlin, Angela DeMichele & Lewis A. Chodosh

  5. Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Dezhen Wang, Peining Xu & Clementina Mesaros

Authors
  1. Saisai Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matt R. Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher J. Sterner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George K. Belka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dezhen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peining Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amulya Sreekumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tien-chi Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dhruv K. Pant
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Igor Makhlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Angela DeMichele
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Clementina Mesaros
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Lewis A. Chodosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SC performed tissue culture work, immunofluorescence, western blotting, droplet digital PCR, and cAMP measurements. MRP, TP, and DKP performed computational analyses of patient and mouse datasets. MRP generated visual representations of computational datasets. SC, CJS, and GKB performed animal work. AD designed and implemented the METAMORPH study. IM and AD curated data from the METAMORPH study. DW, PX, and CM performed liquid chromatography-high resolution mass spectrometry. CM contributed to the visualization of sphingolipid quantities. AS validated experimental models. SC and LAC designed experiments and wrote the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Lewis A. Chodosh.

Ethics declarations

Ethics approval and consent to participate

Animal care and experiments were performed with the approval of, and in accordance with, guideline of the University of Pennsylvania IACUC.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests relevant to the topic of this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Figure S1. Validating PAQR8/Paqr8 overexpression and knockout. a Western blot showing anti-HA tagged PAQR8/Paqr8 and anti-β-tubulin loading control. b Synthego ICE analysis results for Paqr8 knockout cells showing guide target sequence, PAM sequence, indel %, and knockout score. c TIDE sequencing results showing relative proportion of specific indels.

Additional file 2:

Paqr8 does not affect the rate of primary tumor growth in the presence of Her2 expression. nu/nu mice were orthotopically injected with Her2-dependent primary mouse cells. Doxycycline in the drinking water maintained Her2 expression during primary tumor formation. Time from injection to palpation of 5x5mm primary tumors is shown.

Additional file 3:

Paqr8 does not affect cell proliferation following acute Her2 withdrawal in vivo. nu/nu mice harboring Paqr8-OE or Paqr8-KO tumors from orthotopically injected Her2-dependent primary mouse cells three days following Her2 downregulation. Mice were injected with 50mg/kg EdU (i.p.) 2h prior to sacrifice. Residual lesions were harvested, sectioned, and stained by immunofluorescence for EdU and Ki67. Representative images are shown.

Additional file 4:

Paqr8 does not affect proliferation following acute Her2 downregulation in vitro. Her2-dependent primary mouse cells were cultured in 1% serum without doxycycline (Her2 OFF) for 72h and incubated with 10mM EdU for 2h prior to fixation, permeabilization, and staining for EdU and Ki67. Representative images are shown.

Additional file 5:

Paqr8 does not affect rates of apoptosis or cell proliferation in the presence of Her2 expression in vivo or in vitro. nu/nu mice harboring 5x5mm primary tumors from orthotopically injected Her2-dependent Paqr8-OE (a, c) or Paqr8-KO (b, d) primary mouse tumor cells were injected with 50mg/kg EdU (i.p.) 2h prior to sacrifice. Primary tumors were harvested, sectioned, and stained by immunofluorescence for cleaved caspase-3 (cc3), EdU, and Ki67. a-d Percentage of eGFP+ cells that were cc3+, EdU+, or Ki67+ as indicated. Paqr8-OE (e, g) or Paqr8-KO (f, h) Her2-dependent primary cells were cultured in the presence of 10% serum with doxycycline (Her2 ON) and incubated with 10mM EdU for 2h prior to fixation, permeabilization, and staining for cc3, EdU, and Ki67. e-h Percentage of eGFP+ that were cc3+, EdU+, or Ki67+, as indicated.

Additional file 6:

a Proportion of plated MCF7 cells that formed colonies in +PhR csFBS, -PhR csFBS, or -PhR csFBS +E2 medium. b Viable cell count of BT474-M1 cells in +PhR FBS, -PhR csFBS, or -PhR csFBS +E2 medium. c Proportion of MCF7 cells plated that formed colonies in fulvestrant or vehicle control (DMSO).

Additional file 7:

PAQR8 does not affect proliferation of MCF7 cells following 72h of estrogen deprivation in vitro. MCF7 cells were cultured in either growth medium containing phenol red and fetal bovine serum (+PhR FBS) or estrogen-deprived medium without phenol red containing charcoal-stripped fetal bovine serum (-PhR csFBS) for 72h. Cells were incubated with 10mM EdU for 2h prior to fixation, permeabilization, and immunofluorescence staining for EdU and Ki67. Representative images are shown.

Additional file 8:

Effects of Paqr8 on viable cell count following 72h of Her2 withdrawal do not depend on presence of progesterone or estrogen. Her2-dependent primary mouse tumor cells were cultured without doxycycline (Her2 OFF) for 72h. Media contained 1% charcoal-stripped FBS (csFBS), in the presence of 1mM progesterone (P4), 1nM estrogen (E2), or neither.

Additional file 9:

PAQR8 does not affect proliferation of MCF7 cells in primary tumors formed in NSG mice without estrogen supplementation. NSG mice harboring orthotopic MCF7 tumors were injected with 50mg/kg of EdU (i.p.) 2h prior to sacrifice. Tumors were harvested and fixed in 4% paraformaldehyde, paraffin embedded, sectioned and stained by immunofluorescence for EdU and Ki67. Representative images are shown.

Additional file 10:

a Proportion of plated SUM159 cells that formed colonies in the presence of doxorubicin or vehicle control (DMSO). b Proportion of plated SUM159 cells that formed colonies in the presence of docetaxel or vehicle control (DMSO). c Proportion of plated MCF7 cells that formed colonies in the presence of doxorubicin, docetaxel, or vehicle control (DMSO). d Viable cell counts of BT474-M1 cells in the presence of doxorubicin, docetaxel, or vehicle control (DMSO).

Additional file 11:

Full western blot image corresponding to Figure S1a.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, S., Paul, M.R., Sterner, C.J. et al. PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Breast Cancer Res 25, 1 (2023). https://doi.org/10.1186/s13058-022-01559-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13058-022-01559-3

Keywords

  • Breast cancer
  • Tumor recurrence
  • Treatment resistance
  • Endocrine therapy
  • Translational research

Breast Cancer Research

ISSN: 1465-542X

Contact us